Novel drug developmental strategies for treatment‐resistant depression
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Major depressive disorder is a leading cause of disability worldwide. Because conventional therapies are ineffective in many patients, novel strategies are needed to overcome treatment‐resistant depression (TRD). Limiting factors of successful drug development in the last decades were the lack of (1) knowledge of pathophysiology, (2) translational animal models and (3) objective diagnostic biomarkers. Here, we review novel drug targets and drug candidates currently investigated in Phase I–III clinical trials. The most promising approaches are inhibition of glutamatergic neurotransmission by NMDA and mGlu 5 receptor antagonists, modulation of the opioidergic system by κ receptor antagonists, and hallucinogenic tryptamine derivates. The only registered drug for TRD is the NMDA receptor antagonist, S‐ketamine, but add‐on therapies with second‐generation antipsychotics, certain nutritive, anti‐inflammatory and neuroprotective agents seem to be effective. Currently, there is an intense research focus on large‐scale, high‐throughput omics and neuroimaging studies. These results might provide new insights into molecular mechanisms and potential novel therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“The pronounced recovery of synaptogenesis might mediate many of the prolonged effects (Li et al., 2010; Pryazhnikov et al., 2018), which is also supported by the fact that long-lasting beneficial actions occur hours after ketamine is eliminated from the body (Fagerholm et al., 2021; for review, see…”
BackgroundCross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023 · cited 2×
“More recently, the efficacy of antidepressant augmentation with minocycline was tested in TRD patients with a 4-week, placebo-controlled, randomized clinical trial, but changes in HAM-D scores and the proportion of partial responders did not differ between the study arms (Nettis et al., 2021).”
BackgroundThe neuroactive potential of the human gut microbiota in quality of life and depression
Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y., Schiweck, C., Kurilshikov, A., Joossens, M., Wijmenga, C., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0337-x · Cited by 1,963
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 33×
“Its effect in MDD patients has not been published (Wilkinson & Sanacora, 2019) and has not yet been investigated in TRD (Table 1).”
BackgroundInfluentialKelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J., Beers, S., Scott, K., Moloney, G., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.019 · Cited by 1,683
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 2×
“A double-blind, placebo-controlled, randomized clinical trial tested the TNF antagonist infliximab to treat TRD (Raison et al., 2013).”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“…and anxiety symptoms, and therefore, it is considered to be a promising and safe agent, even relevant for first-line treatment (2013-003196-35, Carhart-Harris et al., 2016, 2018; Vargas et al., 2020), where a psychological support therapy comprising three parts (preparation, acute and…”
BackgroundDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 5×
“For other somatic therapies, stimulation therapies, particularly ECT and repetitive transcranial magnetic stimulation, have been found to be effective in TRD (most recently reviewed by Voineskos et al., 2020, and Goh et al., 2020).”
BackgroundInfluentialDuman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026 · cited 1×
“Clinical studies reported altered glutamate levels in the brains of depressed patients using in vivo proton magnetic resonance spectroscopy (Moriguchi et al., 2019), and post-mortem studies found expressional changes of NMDA receptors (Duman et al., 2019; Feyissa et al., 2009).”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 1×
“…and anxiety symptoms, and therefore, it is considered to be a promising and safe agent, even relevant for first-line treatment (2013-003196-35, Carhart-Harris et al., 2016, 2018; Vargas et al., 2020), where a psychological support therapy comprising three parts (preparation, acute and…”
BackgroundPalhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852 · cited 1×
“TRD patients exhibit a higher rate of comorbid psychiatric and general medical conditions, and self-harming behaviour not resulting in death compared with non-TRD patients (Döme et al., 2021; Parker & Graham, 2015).”
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · cited 1×
“Memantine is a well-known compound used in Alzheimer's disease for the symptomatic treatment of cognitive dysfunction (Vaz & Silvestre, 2020).”
BackgroundKazemi, A., Noorbala, A. A., Azam, K., Eskandari, M. H., & Djafarian, K. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.04.010 · Cited by 534 · cited 1×
“Similarly, therapeutic application of probiotics to reduce depressive symptoms is another promising tactic because metabolic activity of gut microbiota seems to regulate epigenetic mechanisms of host tissues (Bambling et al., 2017; Kazemi et al., 2019; Miro-Blanch & Yanes, 2019).”
BackgroundSouery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521
The effects of probiotics on depressive symptoms in humans: a systematic review
Wallace, C. J. K., & Milev, R. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0138-2 · Cited by 471 · cited 1×
“Rapidly accumulating evidence documents that psychobiotic therapy, that is, nurturing gut microbiome with prebiotic treatment, can have an antidepressant-like effect (Wallace & Milev, 2017), but to the best of our knowledge, probiotic therapy has not yet been tested in TRD patients.”
BackgroundSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · cited 1×
“In another study of 17 TRD patients, increased SPECT blood flow was detected 8 h after a single administration in brain areas related to mood regulation, accompanied by significantly reduced depression severity for 21 days after administration (Sanches et al., 2016).”
BackgroundManagement of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
Yuan, N., Chen, Y., Xia, Y., Dai, J., & Liu, C. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0570-y · Cited by 428
Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421 · cited 2×
“Clinical studies reported altered glutamate levels in the brains of depressed patients using in vivo proton magnetic resonance spectroscopy (Moriguchi et al., 2019), and post-mortem studies found expressional changes of NMDA receptors (Duman et al., 2019; Feyissa et al., 2009).”
BackgroundPhillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418 · cited 1×
“…ratio changes in the pregenual anterior cingulate cortex, nucleus accumbens entropy and insulin/mTOR/GSK3β signalling (Johnson et al., 2016; Lewis et al., 2019; Li et al., 2016; Phillips et al., 2019; Roy et al., 2020; Vande Voort et al., 2016; see details in Tables 1 and 2).”
BackgroundEpigenetics of the depressed brain: role of histone acetylation and methylation
Sun, H., Kennedy, P. J., & Nestler, E. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.73 · Cited by 413 · cited 1×
“…in post-mortem brain samples of patients with MDD also revealed disruptions of neuronal and glial plasticity, growth factors and circadian rhythm (Bunney et al., 2015; Duman & Duman, 2015), as well as regulatory changes of microRNAs (Dwivedi, 2014) and epigenetic signatures (Sun et al., 2013).”
BackgroundKetamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
Animal models of major depression and their clinical implications
Czéh, B., Fuchs, E., Wiborg, O., & Simon, M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.04.004 · Cited by 375 · cited 33×
“Its effect in MDD patients has not been published (Wilkinson & Sanacora, 2019) and has not yet been investigated in TRD (Table 1).”
BackgroundInfluentialSelf-citationGut microbiota and major depressive disorder: a systematic review and meta-analysis
Sanada, K., Nakajima, S., Kurokawa, S., Barceló-Soler, A., Ikuse, D., Hirata, A., Yoshizawa, A., Tomizawa, Y., Salas-Valero, M., Noda, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.102 · Cited by 372
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Isingrini, E., Camus, V., Le Guisquet, A.-M., Pingaud, M., Devers, S., & Belzung, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010404 · Cited by 277 · cited 1×
“Another approach was to apply a high-fat diet (45% fat) to mice in combination with the chronic mild stress protocol, and this high-fat diet protocol could prevent the antidepressant effect of fluoxetine (Isingrini et al., 2010).”
MethodEpigenetic aging in major depressive disorder
Han, L. K. M., Aghajani, M., Clark, S. L., Chan, R. F., Hattab, M. W., Shabalin, A. A., Zhao, M., Kumar, G., Xie, L. Y., Jansen, R., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060595 · Cited by 260 · cited 2×
“While epigenetic changes that are observed in peripheral blood samples are often in harmony with the alterations found in the brain (Han et al., 2018), the question still remains as to how well the findings from peripheral blood samples mirror the neurobiological underpinnings of MDD.”
BackgroundZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
Sukoff Rizzo, S. J., Neal, S. J., Hughes, Z. A., Beyna, M., Rosenzweig-Lipson, S., Moss, S. J., & Brandon, N. J. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.120 · Cited by 241
Sanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236
Nettis, M. A., Lombardo, G., Hastings, C., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A., Kose, M., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00948-6 · Cited by 235 · cited 1×
“The compound has a long half-life time (31–42 h) and shows no accumulation and food does not influence its plasma level (Nicholas et al., 2011).”
BackgroundAleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228 · cited 1×
“4.1.4 | Drugs acting at the AMPA receptor There is increasing evidence that the rapid antidepressant action of ketamine is partly mediated by AMPA receptors (Aleksandrova et al., 2017).”
BackgroundInfluentialKrystal, A. D., Pizzagalli, D. A., Smoski, M., Mathew, S. J., Nurnberger, J., Lisanby, S. H., Iosifescu, D., Murrough, J. W., Yang, H., Weiner, R. D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0806-7 · Cited by 227
Epigenetic Regulation at the Interplay Between Gut Microbiota and Host Metabolism
Miro-Blanch, J., & Yanes, O. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00638 · Cited by 195 · cited 1×
“Clinical studies reported altered glutamate levels in the brains of depressed patients using in vivo proton magnetic resonance spectroscopy (Moriguchi et al., 2019), and post-mortem studies found expressional changes of NMDA receptors (Duman et al., 2019; Feyissa et al., 2009).”
BackgroundCholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
Dulawa, S. C., & Janowsky, D. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0219-x · Cited by 187
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Wilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173 · cited 3×
“The modulation with deuterium, an isotope of hydrogen, can lead to further attenuation of the first-pass effect and the quinidine dose can also be reduced (Garay et al., 2017; Wilkinson & Sanacora, 2019).”
BackgroundEpigenetic signaling in psychiatric disorders: stress and depression
Bagot, R. C., Labonté, B., Peña, C. J., & Nestler, E. J. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/rbagot · Cited by 171
Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications
Dwivedi, Y. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/ydwivedi · Cited by 169 · cited 2×
“, 2015; Duman & Duman, 2015), as well as regulatory changes of microRNAs (Dwivedi, 2014) and epigenetic signatures (Sun et al.”
BackgroundTreatment-Resistant Depression and Mortality After Acute Coronary Syndrome
Carney, R. M., & Freedland, K. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081239 · Cited by 163 · cited 1×
“Also, TRD patients have a significantly higher rate of mortality due to external causes, that is, suicide and accidents (Döme et al., 2021; Reutfors et al., 2018), and after acute coronary syndrome (Carney & Freedland, 2009; Scherrer et al., 2012).”
BackgroundBartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
Acetyl- l -carnitine deficiency in patients with major depressive disorder
Nasca, C., Bigio, B., Lee, F. S., Young, S. P., Kautz, M. M., Albright, A., Beasley, J., Millington, D. S., Mathé, A. A., Kocsis, J. H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801609115 · Cited by 152 · cited 1×
“NO-cGMP-KATP channels and the PPARγ receptor might also be involved in the simvastatin-induced antidepressant effect, which also potentiated the action of fluoxetine (Naserzadeh et al., 2019).”
BackgroundBrown, S., Rittenbach, K., Cheung, S., McKean, G., MacMaster, F. P., & Clement, F. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719828965 · Cited by 151
Kautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Fabbri, C., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12959 · Cited by 148 · cited 2×
“…comorbid anxiety, inpatient status, the higher number of antidepressants administered previously and lifetime depressive episodes, as well as longer duration of the current episode were the strongest clinical predictors of treatment resistance in a large multinational sample (Kautzky et al., 2019).”
BackgroundNovel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133 · cited 1×
“Although the results are not officially published, another publication mentioned this trial, in which basimglurant was well tolerated and showed a tendency of positive effect (Quiroz et al., 2016) (Table 1).”
ResultSanacora, G., Johnson, M. R., Khan, A., Atkinson, S. D., Riesenberg, R. R., Schronen, J. P., Burke, M. A., Zajecka, J. M., Barra, L., Su, H.-L., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.224 · Cited by 120 · cited 1×
“Two Phase II studies (NCT00491686 and NCT00986479) were performed approximately 10 years ago, but despite favourable pharmacokinetics, they did not show significant effect (Agbo et al., 2017; Sanacora et al., 2014, 2017; Zarate, Duman, et al., 2013) (Table 1).”
BackgroundSustained Effects of Rapidly Acting Antidepressants Require BDNF-Dependent MeCP2 Phosphorylation
Kim, J.-W., Autry, A. E., Na, E. S., Adachi, M., Björkholm, C., Kavalali, E. T., & Monteggia, L. M. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00868-8 · Cited by 113
Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222463 · Cited by 107
Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden
Reutfors, J., Andersson, T. M.-L., Brenner, P., Brandt, L., DiBernardo, A., Li, G., Hägg, D., Wingård, L., & Bodén, R. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.030 · Cited by 94
Balestrino, M., & Adriano, E. (2019) · Medicinal Research Reviews · doi:10.1002/med.21590 · Cited by 90
Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation
Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126859 · Cited by 88 · cited 2×
“These findings suggest that direct activation of mTORC1 signalling might be effective for depression therapy (Hasegawa et al., 2019; Kato et al., 2019), but Phase I/II study (NCT03606395) results have not yet confirmed the beneficial effect in humans (Table 1).”
BackgroundInfluentialThe impact of Ayahuasca on suicidality: results from a randomized controlled trial
Zeifman, R. J., Palhano-Fontes, F., Hallak, J., Arcoverde, E., Maia-Oliveira, J. P., & Araujo, D. B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01325 · Cited by 87 · cited 3×
“In a randomized trial of TRD patients with increased salivary cortisol levels, a single ayahuasca administration (containing on average 0.36 ± 0.01 mg ml 1 of N,N-dimethyltryptamine, 1.86 ± 0.11 mg ml 1 of harmine, 0.24 ± 0.03 mg ml 1 of harmaline and 1.20 ± 0.05 mg ml 1 of tetrahydroharmine) significantly improved th…”
BackgroundInfluentialFogaça, M. V., Fukumoto, K., Franklin, T., Liu, R.-J., Duman, C. H., Vitolo, O. V., & Duman, R. S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0501-x · Cited by 82
Creatine for the Treatment of Depression
Kious, B. M., Kondo, D. G., & Renshaw, P. F. (2019) · Biomolecules · doi:10.3390/biom9090406 · Cited by 74 · cited 2×
“There are only mild side effects: nausea, diarrhoea, muscle cramps, hypomania/mania, peripheral oedema and increase of serum creatinine level induced by creatine (Hellem et al., 2015; Kious et al., 2019).”
BackgroundMurrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62
Towards translational rodent models of depression
O’Leary, O. F., & Cryan, J. F. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1587-9 · Cited by 60 · cited 1×
“Decades of research have been invested in developing various types of clinically relevant models for MDD (Czéh et al., 2016; Nestler & Hyman, 2010; O'Leary & Cryan, 2013; Pryce & Fuchs, 2016; Willner, 1997).”
BackgroundPhosphorylation of MeCP2 at Ser421 Contributes to Chronic Antidepressant Action
Hutchinson, A. N., Deng, J. V., Cohen, S., & West, A. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2156-12.2012 · Cited by 53 · cited 1×
“…demonstrated that BDNF-dependent methyl-CpG-binding protein 2 (MeCP2) phosphorylation seems to be essential in synaptogenesis and consequent sustained antidepressant actions of ketamine, similarly to scopolamine (Johnson & Liston, 2021; Kim et al., 2021) and imipramine (Hutchinson et al., 2012).”
BackgroundCepeda, M. S., Reps, J., Fife, D., Blacketer, C., Stang, P., & Ryan, P. (2018) · Depression and Anxiety · doi:10.1002/da.22705 · Cited by 50 · cited 2×
“, whether medications should be taken from the same or various pharmacological classes), across the TRD definitions (Cepeda et al., 2018; Dold & Kasper, 2017; Kautzky et al., 2019; Malhi & Mann, 2018; Reutfors et al., 2018, 2019; Souery & Pitchot, 2013).”
BackgroundCreatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1100471 · Cited by 49
Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts
Nagele, P., Zorumski, C. F., & Conway, C. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000837 · Cited by 43
de Boer, J. N., Vingerhoets, C., Hirdes, M., McAlonan, G. M., Amelsvoort, T. V., & Zinkstok, J. R. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.06.020 · Cited by 38
NV-5138 as a fast-acting antidepressant via direct activation of mTORC1 signaling
Hasegawa, Y., Zhu, X., & Kamiya, A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129702 · Cited by 20 · cited 3×
“These findings suggest that direct activation of mTORC1 signalling might be effective for depression therapy (Hasegawa et al., 2019; Kato et al., 2019), but Phase I/II study (NCT03606395) results have not yet confirmed the beneficial effect in humans (Table 1).”
BackgroundInfluential
Cited by
Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“In the clinical setting, significant efforts have been undertaken toward establishing the efficacy, feasibility, and safety of glutamatergic interventions for MDD and TRD, with intravenous ketamine and intranasal s-ketamine researched the most extensively (19).”
BackgroundInfluentialBoyko, M., Gruenbaum, B. F., Frank, D., Natanel, D., Negev, S., Azab, A. N., Barsky, G., Knyazer, B., Kofman, O., & Zlotnik, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065897 · Cited by 27
Esketamine combined with SSRI or SNRI for treatment-resistant depression
Del Casale, A., Spirito, S., Arena, J. F., Preissner, S., Borro, M., Gentile, G., Modesti, M. N., Preissner, R., Ferracuti, S., & Simmaco, M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0200 · Cited by 23
Tian, J., Xie, Y., Ye, S., Hu, Y., Feng, J., Li, Y., Lou, Z., Ruan, L., & Wang, Z. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151965 · Cited by 10
Metadata
- Authors
- Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2022-01-26
- Volume
- 179
- Issue
- 6
- Pages
- 1146-1186
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3216258226
- Cited by
- 106
- References
- 69
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.